Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN) + BEVACIZUMAB (AVASTIN) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER

Next Previous
X
Search
Trial Profile

A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN) + BEVACIZUMAB (AVASTIN) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Eribulin (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms ESMERALDA

    • Most Recent Events

    • 11 Oct 2016 Results of this study, presented at the 41st European Society for Medical Oncology Congress.
    • 16 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 14 Jan 2015 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top